Several genetic abnormalities may confer resistance to EGFR drugs in advanced colorectal cancer
This article was originally published in Scrip
Executive Summary
Advanced colorectal cancer patients with certain genetic abnormalities are unlikely to benefit from therapy with the EGFR-targeted drugs, Lilly (ImClone's) Erbitux (cetuximab) and Amgen's Vectibix (panitumumab), suggests a retrospective analysis that was highlighted in a plenary session at the American Association for Cancer Research (AACR) meeting in Denver.